HK1204477A1 - Single domain antibodies as inhibitors of pcsk9 pcsk9 - Google Patents
Single domain antibodies as inhibitors of pcsk9 pcsk9Info
- Publication number
- HK1204477A1 HK1204477A1 HK15104974.5A HK15104974A HK1204477A1 HK 1204477 A1 HK1204477 A1 HK 1204477A1 HK 15104974 A HK15104974 A HK 15104974A HK 1204477 A1 HK1204477 A1 HK 1204477A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pcsk9
- inhibitors
- single domain
- domain antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
- G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161578000P | 2011-12-20 | 2011-12-20 | |
PCT/CA2012/050923 WO2013091103A1 (fr) | 2011-12-20 | 2012-12-20 | Anticorps à domaine unique en tant qu'inhibiteurs de pcsk9 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1204477A1 true HK1204477A1 (en) | 2015-11-20 |
Family
ID=48667583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15104974.5A HK1204477A1 (en) | 2011-12-20 | 2015-05-26 | Single domain antibodies as inhibitors of pcsk9 pcsk9 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9879093B2 (fr) |
EP (1) | EP2794661B1 (fr) |
JP (1) | JP6170940B2 (fr) |
CN (1) | CN104169304A (fr) |
CA (1) | CA2859226C (fr) |
HK (1) | HK1204477A1 (fr) |
WO (1) | WO2013091103A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
WO2014150983A2 (fr) * | 2013-03-15 | 2014-09-25 | Amgen Inc. | Protéines de liaison à un antigène humain se liant à la proprotéine convertase subtilisine kexine de type 9 |
WO2015017791A1 (fr) * | 2013-08-01 | 2015-02-05 | Atherotech, Inc. | Analyse de la fonction de pcsk9 |
GB2521356B (en) * | 2013-12-17 | 2018-10-10 | Kymab Ltd | Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods |
US9546211B2 (en) * | 2014-10-23 | 2017-01-17 | Singh Molecular Medicine, Llc | Single domain antibodies directed against TNF-alpha |
BR112017020091A2 (pt) | 2015-03-20 | 2018-11-06 | Aarhus Universitet | inibidores de pcsk9 para tratamento de distúrbios do metabolismo de lipoproteínas |
AU2016239948B2 (en) | 2015-03-31 | 2022-03-17 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
WO2016156474A1 (fr) * | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptide comprenant un domaine variable de chaîne d'immunoglobuline qui se lie à la toxine a de clostridium difficile |
CN107438620A (zh) * | 2015-03-31 | 2017-12-05 | 韦斯夸尔德有限公司 | 多肽 |
HUE051896T2 (hu) | 2015-07-16 | 2021-03-29 | Inhibrx Inc | Multivalens és multispecifikus DR5-kötõ fúziós fehérjék |
JP7032662B2 (ja) | 2015-12-31 | 2022-03-09 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Pcsk9抗体、その抗原結合フラグメント及び医薬用途 |
US20200270365A1 (en) * | 2016-01-05 | 2020-08-27 | Jiangsu Hengrui Medicine Co., Ltd. | Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof |
AU2017329799A1 (en) | 2016-09-20 | 2019-04-11 | Aarhus Universitet | Compounds for treatment of lipoprotein metabolism disorders |
BR112019020148A2 (pt) | 2017-04-13 | 2020-05-05 | Cadila Healthcare Ltd | peptídeo |
CN109897110B (zh) * | 2017-12-08 | 2022-05-17 | 深圳华大生命科学研究院 | 纳米抗体及其制备方法 |
CN110872353B (zh) * | 2018-09-03 | 2021-05-04 | 深圳华大基因科技有限公司 | 特异性结合pcsk9抗原的纳米抗体及其制备方法和应用 |
SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
WO2020254827A1 (fr) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
CA3144566A1 (fr) | 2019-06-21 | 2020-12-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
WO2021159235A1 (fr) * | 2020-02-10 | 2021-08-19 | 深圳华大生命科学研究院 | Anticorps à domaine unique pour pcsk9 et son application |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2087413A1 (fr) | 1992-01-17 | 1993-07-18 | Joseph R. Lakowicz | Dosage immunologique fluorimetrique |
MXPA04005134A (es) | 2001-11-30 | 2004-08-11 | Ca Nat Research Council | Novedosas moleculas de auto-montaje. |
JP5588175B2 (ja) * | 2006-11-07 | 2014-09-10 | メルク・シャープ・アンド・ドーム・コーポレーション | Pcsk9のアンタゴニスト |
EP2083859A4 (fr) * | 2006-11-07 | 2010-11-24 | Merck Sharp & Dohme | Antagonistes de pcsk9 |
EP2137218A2 (fr) * | 2007-04-13 | 2009-12-30 | Novartis Ag | Molécules et procédés de modulation de proprotéine convertase subtilisine/kexine de type 9 (pcsk9) |
AU2008316587B2 (en) * | 2007-10-26 | 2014-07-17 | Merck Sharp & Dohme Corp. | Anti-PCSK9 and methods for treating lipid and cholesterol disorders |
TWI516501B (zh) * | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
WO2011020183A1 (fr) | 2009-08-18 | 2011-02-24 | National Research Council Canada | Criblage de protéines candidates |
AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
-
2012
- 2012-12-20 JP JP2014547652A patent/JP6170940B2/ja active Active
- 2012-12-20 US US14/366,345 patent/US9879093B2/en active Active
- 2012-12-20 CA CA2859226A patent/CA2859226C/fr active Active
- 2012-12-20 CN CN201280070110.4A patent/CN104169304A/zh active Pending
- 2012-12-20 EP EP12859390.2A patent/EP2794661B1/fr active Active
- 2012-12-20 WO PCT/CA2012/050923 patent/WO2013091103A1/fr active Application Filing
-
2015
- 2015-05-26 HK HK15104974.5A patent/HK1204477A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2794661A1 (fr) | 2014-10-29 |
CN104169304A (zh) | 2014-11-26 |
WO2013091103A1 (fr) | 2013-06-27 |
US20150017183A1 (en) | 2015-01-15 |
CA2859226A1 (fr) | 2013-06-27 |
JP2015503905A (ja) | 2015-02-05 |
CA2859226C (fr) | 2020-07-21 |
JP6170940B2 (ja) | 2017-07-26 |
US9879093B2 (en) | 2018-01-30 |
EP2794661A4 (fr) | 2015-09-09 |
EP2794661B1 (fr) | 2019-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1204477A1 (en) | Single domain antibodies as inhibitors of pcsk9 pcsk9 | |
SMT201600238B (it) | Inibitori di protein chinasi | |
HK1201519A1 (en) | Inhibitors of phosphodiesterase type 10a 10a | |
AP3907A (en) | 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | |
ZA201309561B (en) | Novel inhibitor compounds of phosphodiestarase type 10a | |
EP2678018A4 (fr) | Combinaison d'inhibiteurs des kinases et utilisations associées | |
SMT201600001B (it) | Imidazopiridazine come inibitori di akt chinasi | |
HK1202529A1 (zh) | 非典型性蛋白激酶 的噻吩並嘧啶類抑制劑 | |
SI2670401T1 (sl) | Postopki uporabe inhibitorjev ALK | |
AP3529A (en) | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors | |
ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
HK1199252A1 (en) | Inhibitors of nedd8-activating enzyme nedd8- | |
ZA201206456B (en) | Uses of dgati inhibitors | |
IL227924A0 (en) | Preparations and methods of use for determining a4he | |
ME02167B (me) | Piridinil- i pirazinil-metiloksi-aril derivati korisni kao inhibitori tirozin kinaze slezine (syk) | |
EP2688901A4 (fr) | Inhibiteurs de 17ss-hsd1, 17ss-hsd3 et 17ss-hsd10 | |
EP2709999A4 (fr) | Composés de quinazoline-7-éther et méthodes d'utilisation | |
HK1199040A1 (en) | Use of antibody | |
EP2591368A4 (fr) | Procédé de détermination de la consommation d'éthanol | |
EP2663322A4 (fr) | Nouvelles utilisations d'inhibiteurs de la cyclophiline | |
ZA201308697B (en) | Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors | |
UA22157S (uk) | Набір посуду для напоїв | |
AU2011903435A0 (en) | Determining of locations |